NASDAQ · CNTA
Centessa Pharmaceuticals plc
$40.50$0.00 (0.0%)
Centessa Pharmaceuticals plc’s quoted price sits in the upper half of its reported 52-week range, 0.15% below the high.
Loading market information…
NASDAQ · APGE · USD
Stock price, earnings
Quote as of Sep 4, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Apogee Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.01% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Apogee Therapeutics, Inc.’s next earnings report is currently expected on Nov 9, 2026, with estimated earnings per share of -$1.14. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Apogee Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:35 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2024 | Mar 3, 2025 | -$1.19-26.6% vs estimate | $0.00 |
|---|
| Q3 2024 | Nov 12, 2024 | -$0.86+2.16% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
14 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 9 contributors · Median target $135.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$40.50$0.00 (0.0%)
Centessa Pharmaceuticals plc’s quoted price sits in the upper half of its reported 52-week range, 0.15% below the high.
$63.47-$0.49 (-0.77%)
CG Oncology Inc.’s quoted price sits in the upper half of its reported 52-week range, 21.61% below the high.
$22.30-$0.23 (-1.02%)
Legend Biotech Corporation’s quoted price sits in the lower half of its reported 52-week range, 40.53% below the high.
$37.54+$1.20 (+3.3%)
Xenon Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.33% below the high.
$69.30-$0.16 (-0.23%)
Celcuity Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.11% below the high.
$82.84-$0.36 (-0.43%)
Disc Medicine, Inc.’s quoted price sits in the upper half of its reported 52-week range, 16.74% below the high.
$53.01$0.00 (0.0%)
Soleno Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 41.31% below the high.
$22.36-$0.68 (-2.95%)
Zai Lab Limited’s quoted price sits in the upper half of its reported 52-week range, 18.69% below the high.
